What DexCom, Inc. told the SEC could break it.

Most Dexcom customers rely on third-party payers (Medicare/Medicaid/CMS, private insurers) to cover CGM costs; cost-containment measures could lower prices/reimbursement rates or shift costs to patients, reducing demand.

“Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+. We expect that these continuing cost reduction and containment measures could result in lower prices for these products and lower reimbursement rates, as well as could lead to patients being unable to obtain approval for coverage or payment from these third-party payors resulting in costs being shifted to patients for these products.”

As a medical-device maker, Dexcom's CGMs require FDA clearance/approval (510(k)/PMA) and compliance with the new QMSR quality system, plus country-by-country international approvals (e.g., EU MDR) that vary substantially.

“The QMSR amends the quality regulations to align more closely with international consensus standards for quality management systems for medical devices used by other regulatory authorities around the world. Class II devices are typically subject to the requirement stated above and additionally may be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling, as well as general controls.”

Dexcom relies on single/sole sources for critical components — the application-specific integrated circuit in its transmitter, applicator seals, and polymers for its sensor biointerface membranes — and some supply agreements can be terminated on short notice.

“we also rely on single and/or sole sources for certain components and materials used in manufacturing, such as for the application-specific integrated circuit that is incorporated into the transmitter and certain polymers used to synthesize the polymeric biointerface membranes for our products. In some cases, our agreements with these and other suppliers can be terminated by either party upon short notice.”

Dexcom discloses customers (distributors) that each represent 10% or more of total revenue and of gross accounts receivable, indicating meaningful customer concentration in its distribution channel.

“The following table sets forth the percentages of total revenue and gross accounts receivable for customers that represent 10% or more of the respective amounts: Revenue* Gross Accounts Receivable”

Most manufacturing is concentrated in Mesa, Arizona and Malaysia (limited in San Diego), with replacement capacity hard to stand up quickly; sites face earthquake/wildfire/water-stress and Malaysia political/site (reclaimed-wetland) risks.

“Additionally, the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California.”